Difference between metoprolol tartrate and metoprolol succinate
Pro Research Analysisby 
Searched over 200M research papers
Differences Between Metoprolol Tartrate and Metoprolol Succinate
Introduction to Metoprolol Tartrate and Metoprolol Succinate
Metoprolol is a beta-blocker commonly used to treat various cardiovascular conditions, including hypertension, angina, and heart failure. It is available in two primary formulations: metoprolol tartrate (MT) and metoprolol succinate (MS). While both forms are effective, they have distinct pharmacokinetic and pharmacodynamic properties that influence their clinical use.
Pharmacokinetic and Pharmacodynamic Properties
Absorption and Release Mechanisms
Metoprolol tartrate is an immediate-release formulation, typically administered twice daily, whereas metoprolol succinate is an extended-release formulation, usually taken once daily. This difference in release mechanisms affects the drug's absorption and duration of action. Metoprolol succinate's extended-release properties allow for more stable plasma concentrations over 24 hours, which can be beneficial for maintaining consistent therapeutic effects Kukin2000Gattis2001.
Molecular and Crystal Structure
The solid-state structures of MT and MS differ significantly. MS exhibits a slightly greater cohesive energy and undergoes reversible anisotropic lattice expansion/contraction upon temperature changes. In contrast, MT expands/contracts isotropically and forms an amorphous solid upon cooling from the melt, taking several days to revert to its crystalline form Paoli2016Rossi2018. These differences can influence the stability and shelf-life of the formulations.
Clinical Efficacy and Safety
Heart Failure and Hemodynamic Effects
Both MT and MS have been shown to produce similar hemodynamic and clinical effects in patients with chronic heart failure. Studies indicate that both formulations improve cardiac function, exercise capacity, and hemodynamic parameters without significant differences in adverse effects Kukin2000Zhichen2013Quan-Y2013. However, MS may offer advantages in terms of more rapid initiation and ease of dosing due to its once-daily administration .
Chronic Obstructive Pulmonary Disease (COPD) and Heart Failure
In patients with COPD complicating chronic heart failure, MS has been found to be more effective in improving cardiac function compared to MT, although both formulations show similar safety profiles . This suggests that MS may be preferable in patients with coexisting pulmonary conditions.
Acute Myocardial Infarction
In the context of acute myocardial infarction, both MT and MS effectively reduce heart rates. However, there is no significant difference in the degree and trend of heart rate reduction between the two formulations over the first 72 hours of treatment .
Hypertension
For patients with mild hypertension, both MT and MS are effective in lowering blood pressure. MS has been shown to significantly reduce the morning blood pressure peak and increase heart rate variability compared to MT, which may offer additional cardiovascular benefits .
Vasospastic Angina
In patients with vasospastic angina, MS has demonstrated a significant reduction in the incidence of clinically significant angina attacks compared to MT. However, there are no significant differences in the rates of adverse cardiovascular events such as myocardial infarction or stroke between the two formulations .
Conclusion
Metoprolol tartrate and metoprolol succinate are both effective beta-blockers with distinct pharmacokinetic and pharmacodynamic properties. While they produce similar clinical outcomes in many cardiovascular conditions, MS's extended-release formulation offers advantages in dosing convenience and potentially more stable therapeutic effects. The choice between MT and MS should be based on individual patient needs, clinical context, and specific therapeutic goals.
Sources and full results
Most relevant research papers on this topic